Neurovascular Intervention

In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban.

赛诺NOVA-DES颅内球扩药物洗脱支架系统具有推送顺畅、容易到位、成形完美等诸多优点，只有严格把握手术指征，了解支架的特性，掌握精准的操作方法，才能充分发挥其优越性，期待此款国产支架给国民带来更好的治疗效果。

Neurovita's NOVA-DES intracranial ball expansion drug-eluting stent system has many advantages such as smooth pushing, easy to place, and perfect forming, etc. Only by strictly grasping the surgical indications, understanding the characteristics of the stent, and mastering the precise operation method can we give full play to its superiority, and we expect this domestic stent to bring better treatment effect to the nation.

Tthis study showed that female sex and a history of hypertension might be associated with unsuccessful recanalization in MT for anterior circulation acute ischemic stroke. Further prospective studies are needed to fully evaluate predictors of recanalization, which may help to develop improved thrombectomy strategies.

The management of intracranial atherosclerotic disease (ICAD) has been evolving with advanced imaging, refinements of best medical treatment, and the development of endovascular options. There has been a significant increase in the use of endovascular therapy for symptomatic ICAD in the USA over the past 6 years. The rationale for this review is to update neurointerventionalists in these areas so that evidence-based decisions can be considered when counseling potential patients regarding their risks, benefits, and potential complications.

HEAL Technology: The next generation of antithrombogenic coating. The HEAL Technology mimics the final step of natural haemostasis and thus the conversion of fibrinogen (by thrombin) to fibrin. The controlled growth process results in a thin and fully polymerised network of fibrin with additional covalently bound heparin molecules.

The treatment of complex intracranial aneurysms with the Pipeline Flex embolization device may be safe and effective, with a high complete occlusion rate, a decreased complication rate, and a good prognosis rate at medium follow-up.

PFT led to reproduceable improvement in clot engagement with an average ∼60% increase in clot traction in this model and was found not to have a significant learning curve.

Statistics show that intracranial atherosclerotic disease (ICAD) accounts for a high proportion of ischemic strokes, especially in the yellow population where about 30% to 50% of ischemic stroke cases are associated with it. In recent years, the use of various types of balloons and stents in ICAD has led to better revascularization rates and lower stenosis rates. However, due to the individual characteristics of balloon and stent interventions, some complications and "restenosis" still exist, limiting the widespread use of ICAD interventions. Some studies have shown that drug balloons and drug stents are relatively "complementary" in the choice of ICAD interventions, giving physicians more options in the choice of devices for different lesions.

Fluid Biomed is commercializing the first polymer-based brain stent to cure aneurysms. Brain aneurysms afflict up to 5% of people and can lead to devastating stroke. The company team of neurosurgeons, scientists, and engineers has designed the world’s first hybrid polymer-metal flow-diverting stent to cure this deadly disease. Uniquely constructed of dissolving polymer and metal, this innovative medical device provides a scaffold to allow better healing and visualization of blood vessels.

Fluid Biotech, founded in 2012 by two Canadian neurosurgeons, is developing an implantable, absorbable dense mesh scaffold to address the shortcomings of traditional dense mesh scaffolds. ReSolv is a self-expanding dense mesh scaffold that is a blend of absorbable polymers and metals. The unique use of polymers in ReSolv allows for better healing of vessels while minimizing interference with radiological examinations.

种可吸收聚合物和金属混合的自膨胀密网支架。 ReSolv具备高度灵活，可导航至大脑细小的血管。ReSolv中独特使用聚合物可以更好地愈合血管，同时最大限度地减少对放射检查的干扰。

Ischemic stroke despite direct oral anticoagulant (DOAC) is increasingly common and portends high risk of subsequent ischemic stroke. Efficacy and safety of antithrombotic regimens following the condition are unclear. We aimed to compare the outcomes of patients with ischemic stroke despite DOAC with and without an alternative antithrombotic regimen, and determine the risk factors of recurrent ischemic stroke while on anticoagulation.

In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.

Combination of EIS and machine learning can reliably predict the RBC composition of retrieved ex vivo AIS thrombi and then classify them into groups according to their RBC composition with good sensitivity and specificity.

The superiority of balloon angioplasty plus aggressive medical management (AMM) to AMM alone for symptomatic intracranial artery stenosis (sICAS) on efficacy and safety profiles still lacks evidence from randomised controlled trials (RCTs).

China NMPA issued the notice “Information Collection from Enterprises and Institutions Related to the Preparation of the Guideline for Intracranial Coils and Guideline for Stent Retrievers” on May 17, 2023. NMPA invites domestic and foreign enterprises, research, and clinical institutions, etc. to actively participate, to provide feedback in the submission materials and technical review requirements.

Our results show that the combination treatment significantly improved restoration of neurological deficits in the animal stroke model. However, further studies are required to see if EA could promote the rapid differentiation of BMSC into neural stem cells in the short term.

Our study provides the first comprehensive summary for the last thirty years and the prediction of the global burden of IS and its attributable risk factors until 2030, providing detailed statistics for decision-making on the prevention and control of IS globally. Inadequate control of the seven risk factors would lead to an increased disease burden of IS in young people, especially in low SDI regions. Our study identifies high-risk populations and helps public health professionals develop targeted preventive strategies to reduce the global disease burden of ischemic stroke.

Ischaemic strokes, the most common where a clot cuts blood supply to the brain, will be claiming up to 6.4 million lives a year at the end of the decade. This compares to two million in 1990 - and more than three million in 2019.

Induction of anaesthesia and its associated spikes in blood pressure can cause rupture of an aneurysm during intracranial surgery. Lidocaine can reportedly provide hemodynamic stability when applied before endotracheal intubation. Rapid injection of large doses of lidocaine can cause unconsciousness.

The Q revascularisation system combines the company’s Q aspiration catheter with its Super 90 guide catheter, and is designed to provide up to twice the aspiration power of traditional aspiration catheters—and features simple and fast setup, prep, and operation, MIVI claims.

The Q™ Revascularization System combines the MIVI Q™ Aspiration Catheter with the MIVI Super 90 Guide Catheter. The System is designed to provide up to twice the aspiration power of traditional aspiration catheters and features simple and fast set up, prep, and operation.

Early hyperemia is a potential marker for cerebrovascular injury and may help select patients for adjunctive therapy to prevent edema, reperfusion injury, and lesion growth.

San Mateo, California, RapidAI company said this represents the “first and only” device green-lit for pinpointing suspected intracranial hemorrhage and large vessel occlusion via imaging. RapidAI said the product will allow care teams to make critical decisions on triage and transfer faster, significantly reducing the time between scans and subsequent treatment.

On April 18, 2023, the Ghunter™ intracranial clot retrieval stent developed by Sano Medical Technology Co., Ltd (hereinafter referred to as "Sano Shenchang"), a subsidiary of Sano Medical Technology Co., Ltd (hereinafter referred to as "Sano Shenchang"), was approved by the State Drug Administration (NMPA) of China, further enriching the company's product layout in the field of acute ischemic stroke treatment.

2023年4月18日，由赛诺医疗科学技术股份有限公司控股子公司赛诺神畅医疗科技有限公司（以下简称“赛诺神畅”）自主研发的Ghunter™颅内取栓支架获得中国国家药品监督管理局（NMPA）批准上市，进一步丰富公司在急性缺血性脑卒中治疗领域的产品布局，Ghunter™颅内取栓支架作为神经介入术者不可多得的国产取栓器械，帮助术者捕捉各类血栓，惠及广大AIS患者。

While a number of companies in the neurovascular space have become increasingly focused on the ‘first-pass effect’ in mechanical thrombectomy treatments, many major clinical trials assessing the safety and efficacy of the technique still favour a ‘rule-of-three’ paradigm. And—although it is now broadly accepted that the risk of a poorer clinical outcome grows with every additional clot-retrieval attempt—the exact relationship between the two is still highly debatable.